Arcus Biosciences stock gains on TD Cowen buy rating

Arcus Biosciences stock experienced gains following a buy rating issued by TD Cowen. Similarly, First Tracks Biotherapeutics saw its stock price rise after receiving a buy rating from Guggenheim. Both biotechnology companies witnessed positive market reactions as a direct result of these favorable analyst assessments from their respective financial institutions. These ratings have contributed to the upward movement of the shares for both Arcus Biosciences and First Tracks Biotherapeutics in the current trading session.